drug

GSK239512

MeSH C584220
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by GlaxoSmithKline
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Investigational (via trials)
SchizophreniaSchizophrenia

Trials

1
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
NCT01009060Phase 2Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
GlaxoSmithKline
company
trial
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication